Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02950480 · ClinicalTrials.gov registry record · Phase 2
Breast Capsular Contracture Following Post-Mastectomy Reconstruction in Women Treated With the Leukotriene Inhibitor Zafirlukast: A Phase II Trial
A Phase 2 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT02950480 is a Phase 2 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 4 participants.
The verdict
NCT02950480, a Phase 2 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
A 2 arm, 90 patient (45 per cohort) trial in patients with breast cancer who will be undergoing mastectomy with immediate tissue-expander reconstruction to determine whether treatment with zafirlukast (20mg PO BID) can reduce or prevent the development of capsular contracture.
Interventions
- DRUG zafirlukast
- OTHER Standard of Care (no intervention)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2017-03-13 |
| Est. Completion | 2018-12-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02950480
The ClinicalTrials.gov registry entry for NCT02950480 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which zafirlukast is the first listed.
NCT02950480 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02950480 about?
NCT02950480 is a clinical study titled "Breast Capsular Contracture Following Post-Mastectomy Reconstruction in Women Treated With the Leukotriene Inhibitor Zafirlukast: A Phase II Trial". A 2 arm, 90 patient (45 per cohort) trial in patients with breast cancer who will be undergoing mastectomy with immediate tissue-expander reconstruction to determine whether treatment with zafirlukast (20mg PO BID) can reduce or prevent the development of capsular contracture.
What is the current status of trial NCT02950480?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2017-03-13. Estimated completion is 2018-12-20.
What interventions are being tested in trial NCT02950480?
The interventions under investigation include: zafirlukast (DRUG), Standard of Care (no intervention) (OTHER).
Who is sponsoring clinical trial NCT02950480?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.